Diffuse Amyloid Deposits In Alzheimer'S Disease is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Diffuse amyloid deposits represent the earliest form of amyloid-beta (Aβ) pathology in Alzheimer's disease (AD). These non-fibrillar, non-compact plaques are thought to precede and potentially contribute to the formation of neuritic plaques and subsequent neurodegeneration.
- Structure: Non-fibrillar Aβ aggregates
- Thioflavin S: Negative (no β-sheet)
- Location: Cortical layers, hippocampus
- Cellular association: Primarily extracellular
- Size: Small, punctate deposits
- Composition: Pre-aggregated Aβ oligomers
- Progression: May evolve into plaques
- Core: Dense Aβ fibrils
- Halo: Dystrophic neurites
- Association: Reactive glia
- Correlation: Cognitive decline
- Aβ40: Predominant in diffuse deposits
- Aβ42: More aggregation-prone
- N-terminal modifications: Pyroglutamate
- Isoforms: Various length variants
- Perivascular: Vascular amyloid (CAA)
- Subpial: Surface deposits
- Cortical: Layer-specific patterns
- Subcortical: Less common
- Astrocytes: Reactive gliosis
- Microglia: Chronic activation
- Complement: Inflammatory cascade
- Synaptic dysfunction: Pre-plaque
- Dendritic spine loss: Early event
- Neuritic dystrophy: Associated with plaques
- First pathological change: Diffuse deposits
- Silent accumulation: Years before symptoms
- Biomarker correlation: Amyloid PET positive
- Plaque burden: Less cognitive correlation
- Soluble Aβ: Better correlation
- Network dysfunction: Activity changes
- Campbell-Switzer stain: Specific for diffuse
- Amyloid PET: Florbetapir, Florbetaben
- Cryo-EM: Structural analysis
- CSF Aβ42: Decreased in AD
- Amyloid PET: Standardized uptake
- Plasma Aβ: Emerging biomarkers
- Immunotherapy: Aducanumab, Lecanemab
- Aggregation inhibitors: Branimelast
- Production inhibitors: BACE inhibitors (failed)
- Lifestyle modifications: Risk reduction
- Early intervention: Preclinical treatment
- Vascular health: Reduce CAA
The study of Diffuse Amyloid Deposits In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Pike et al., Diffuse amyloid deposition in Alzheimer's disease (1995)
- Condello et al., Microstructure of diffuse plaques (2019)
- Jucker & Walker, Propagation of Aβ aggregation (2013)
- Masters et al., Amyloid plaque formation in AD (1985)